Abstract
The COVID-19 pandemic magnifies the need for well-conducted clinical trials to identify novel and targeted therapies for critically ill patients. For critical care research, the informed consent process has distinctive challenges that often delay the completion of clinical trials. Most critically ill patients do not have capacity to consent for research participation, given their acute illness and the use of sedative medications, and thus depend on a surrogate for informed consent. Consequently, improving the process of surrogate informed consent for critical care research has been identified as an area of focus to enhance the conduct of clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
